Background: Several recent studies have reported egg yolk-associated food protein-induced enterocolitis syndrome (FPIES) in Japan. We previously reported the usefulness of post-emetic thymus and activation-regulated chemokine (TARC) levels for the diagnosis and evaluation of symptom severity in FPIES caused by solid foods including egg yolk. However, there are no studies on the usefulness of TARC as a prognostic biomarker. Objective: The aim of the study was to evaluate the post-emetic TARC levels, clinical symptoms, and post-index event results of the egg yolk oral food challenge test (OFC), and retrospectively investigate predictive factors of the subsequent OFC result. Method: This retrospective study included 12 patients with egg yolk FPIES. The following long-term management protocol for egg yolk FPIES was mandatory for study inclusion: Patients visited the emergency department, met the diagnostic criteria of FPIES, and underwent an egg yolk OFC 6–12 months after complete elimination of egg yolk. If the result of the OFC was positive, the patient underwent the OFC every year until it was negative. We analyzed a total of 20 episodes (12 department visits and eight positive OFCs). The blood test data, including post-emetic TARC level and symptom severity, were compared between the next-OFC-positive group and the next-OFC-negative group. In addition, tolerance development over follow-up was analyzed. Results: The median (range) ages of the next-OFC-positive and negative groups were 11 (6–33) and 10 (7–21) months, respectively. The median (range) serum TARC (pg/mL) level was 5,208 (2,009–8,147) in the next-OFC-positive group, which was significantly higher (p = 0.004) than that in the next-OFC-negative group, which was 1,803 (905–3,754). There were no significant differences in other hematological results. The next-OFC-positive group had greater severity compared to the next-OFC-negative group (p = 0.026). The remission rate was approximately 30% at 24 months and 80% at 36 months. Conclusion: Post-emetic TARC levels may predict the short-term prognosis of egg yolk FPIES after approximately 1 year and could be useful for the management of egg yolk FPIES.

1.
Nowak-Węgrzyn A, Chehade M, Groetch ME, Spergel JM, Wood RA, Allen K, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: executive summary-workgroup report of the adverse reactions to Foods Committee, American Academy of Allergy, Asthma & Immunology.
J Allergy Clin Immunol
. 2017;139(4):1111–26.e4.
2.
Nishino M, Sato S, Nagakura KI, Takahashi K, Asaumi T, Ogura K, et al. Food protein-induced enterocolitis syndrome triggered by egg yolk and egg white.
Pediatr Allergy Immunol
. 2021;32(3):618–21.
3.
Toyama Y, Ishii T, Morita K, Tsumura Y, Takahashi T, Akashi M, et al. Multicenter retrospective study of patients with food protein-induced enterocolitis syndrome provoked by hen’s egg.
J Allergy Clin Immunol Pract
. 2021;9(1):547–9.e1.
4.
Watanabe Y, Sakai H, Nihei M, Miura K, Kumaki S. Early tolerance acquisition in hen’s egg yolk-associated food protein-induced enterocolitis syndrome.
J Allergy Clin Immunol Pract
. 2021;9(5):2120–2.e2.
5.
Makita E, Kuroda S, Itabashi K, Sugawara D, Ichihashi K. Evaluation of the diagnostic accuracy of thymus and activation-regulated chemokine to discriminate food protein-induced enterocolitis syndrome from infectious gastroenteritis.
Int Arch Allergy Immunol
. 2021;182(3):229–33.
6.
Makita E, Sugawara D, Kuroda S, Itabashi K, Ichihashi K. Usefulness of thymus and activation-regulated chemokine (TARC) for FPIES diagnosis.
Pediatr Allergy Immunol
. 2022;33(1):e13649.
7.
Caubet JC, Cianferoni A, Groetch M, Nowak-Wegrzyn A. Food protein-induced enterocolitis syndrome.
Clin Exp Allergy
. 2019;49(9):1178–90.
8.
Knipping K, Knippels LM, Dupont C, Garssen J. Serum biomarkers for allergy in children.
Pediatr Allergy Immunol
. 2017;28(2):114–23.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.